Item |
Information |
Drug Groups
|
illicit; approved |
Description
|
Clotiazepam is a benzodiazepine derivative, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada. |
Indication |
For the treatment of anxiety disorders. |
Pharmacology |
Clotiazepam is a benzodiazepine derivative possessing anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Stage 2 NREM sleep is significantly increased by clotiazepam. |
Affected Organisms |
• |
Humans and other mammals |
|
Biotransformation |
Hepatic. |
Half Life |
4 hours |
Protein Binding |
99% bound to plasma proteins. |
References |
• |
Nakazawa Y, Kotorii M, Oshima M, Horikawa S, Tachibana H: Effects of thienodiazepine derivatives on human sleep as compared to those of benzodiazepine derivatives. Psychopharmacologia. 1975 Oct 31;44(2):165-71.
[Pubmed]
|
|
External Links |
|